- Home
- FRBA vs PRLD Comparison
FRBA vs PRLD Comparison
Compare FRBA & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRBA | PRLD |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | 336 | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.0M | 529.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FRBA | PRLD |
|---|---|---|
| Price | $17.44 | $3.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $20.00 | $9.20 |
| AVG Volume (30 Days) | 74.0K | ★ 459.2K |
| Earning Date | 10-23-2026 | 11-11-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | $1.31 | $258.83 |
| Revenue Next Year | $4.10 | N/A |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $14.41 | $1.16 |
| 52 Week High | $19.33 | $6.83 |
Technical Indicators
Market Signals| Indicator | FRBA | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 26.44 |
| Support Level | $16.93 | $2.83 |
| Resistance Level | $17.60 | $3.32 |
| Average True Range (ATR) | 0.36 | 0.24 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 47.22 | 1.83 |
Price Performance
Historical ComparisonAbout FRBA First Bank
First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of business. Its services are Business Banking, Personal Banking, Digital Banking, and Lending.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.